ArticleResearch (Washington, D.C.)2024

Eclipsing Toxicity, Enhancing Efficacy: Clofazimine's Vanguard in the Realm of Anti-PD-1 and CTLA-4 Immunotherapy.

Ruirong Tan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.